MX2022016321A - Inhibidores de la calicreina plasmatica. - Google Patents
Inhibidores de la calicreina plasmatica.Info
- Publication number
- MX2022016321A MX2022016321A MX2022016321A MX2022016321A MX2022016321A MX 2022016321 A MX2022016321 A MX 2022016321A MX 2022016321 A MX2022016321 A MX 2022016321A MX 2022016321 A MX2022016321 A MX 2022016321A MX 2022016321 A MX2022016321 A MX 2022016321A
- Authority
- MX
- Mexico
- Prior art keywords
- plasma kallikrein
- compounds
- macular edema
- kallikrein inhibitors
- uveitis
- Prior art date
Links
- 102000003827 Plasma Kallikrein Human genes 0.000 title abstract 3
- 108090000113 Plasma Kallikrein Proteins 0.000 title abstract 3
- 229940127379 Kallikrein Inhibitors Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000002691 Choroiditis Diseases 0.000 abstract 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 206010019860 Hereditary angioedema Diseases 0.000 abstract 1
- 208000001344 Macular Edema Diseases 0.000 abstract 1
- 206010025415 Macular oedema Diseases 0.000 abstract 1
- 208000003971 Posterior uveitis Diseases 0.000 abstract 1
- 229940124639 Selective inhibitor Drugs 0.000 abstract 1
- 206010046851 Uveitis Diseases 0.000 abstract 1
- 201000011190 diabetic macular edema Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 201000010230 macular retinal edema Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000004644 retinal vein occlusion Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063039873P | 2020-06-16 | 2020-06-16 | |
| PCT/US2021/036706 WO2021257353A1 (en) | 2020-06-16 | 2021-06-10 | Plasma kallikrein inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022016321A true MX2022016321A (es) | 2023-01-24 |
Family
ID=79268261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022016321A MX2022016321A (es) | 2020-06-16 | 2021-06-10 | Inhibidores de la calicreina plasmatica. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12459927B2 (https=) |
| EP (1) | EP4164634A4 (https=) |
| JP (1) | JP7776453B2 (https=) |
| KR (1) | KR102931248B1 (https=) |
| CN (1) | CN115989224B (https=) |
| AU (1) | AU2021292449A1 (https=) |
| BR (1) | BR112022025528A2 (https=) |
| CA (1) | CA3182626A1 (https=) |
| MX (1) | MX2022016321A (https=) |
| WO (1) | WO2021257353A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230038526A (ko) | 2020-07-10 | 2023-03-20 | 머크 샤프 앤드 돔 엘엘씨 | 혈장 칼리크레인 억제제 |
| US20230416227A1 (en) * | 2020-09-10 | 2023-12-28 | Merck Sharp & Dohme Llc | Plasma kallikrein inhibitors |
| CN116120272A (zh) * | 2022-12-31 | 2023-05-16 | 淮北师范大学 | 一种合成咯菌腈中间体2,2-二氟-1,3-苯并二噁茂-4-甲醛的方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140378474A1 (en) * | 2012-01-27 | 2014-12-25 | Novartis Ag | 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
| KR102736869B1 (ko) | 2014-03-07 | 2024-12-02 | 바이오크리스트파마슈티컬즈,인코포레이티드 | 인간 혈장 칼리크레인 저해제 |
| GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
| EP3368524B1 (en) | 2015-10-27 | 2021-08-18 | Boehringer Ingelheim International GmbH | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
| DK3464271T3 (da) | 2016-05-31 | 2020-06-15 | Kalvista Pharmaceuticals Ltd | Pyrazolderivater som plasma-kallikreininhibitorer |
| BR112020000463A2 (pt) | 2017-07-13 | 2020-07-21 | Syngenta Participations Ag | derivados oxadiazol microbiocidas |
-
2021
- 2021-06-10 CN CN202180050323.XA patent/CN115989224B/zh active Active
- 2021-06-10 AU AU2021292449A patent/AU2021292449A1/en active Pending
- 2021-06-10 JP JP2022577145A patent/JP7776453B2/ja active Active
- 2021-06-10 EP EP21826734.2A patent/EP4164634A4/en active Pending
- 2021-06-10 KR KR1020237001243A patent/KR102931248B1/ko active Active
- 2021-06-10 BR BR112022025528A patent/BR112022025528A2/pt unknown
- 2021-06-10 WO PCT/US2021/036706 patent/WO2021257353A1/en not_active Ceased
- 2021-06-10 MX MX2022016321A patent/MX2022016321A/es unknown
- 2021-06-10 CA CA3182626A patent/CA3182626A1/en active Pending
- 2021-06-10 US US18/007,787 patent/US12459927B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023531411A (ja) | 2023-07-24 |
| BR112022025528A2 (pt) | 2023-01-17 |
| CA3182626A1 (en) | 2021-12-23 |
| EP4164634A1 (en) | 2023-04-19 |
| JP7776453B2 (ja) | 2025-11-26 |
| US20230286958A1 (en) | 2023-09-14 |
| US12459927B2 (en) | 2025-11-04 |
| KR102931248B1 (ko) | 2026-03-03 |
| CN115989224A (zh) | 2023-04-18 |
| AU2021292449A1 (en) | 2023-02-02 |
| CN115989224B (zh) | 2025-02-25 |
| KR20230024981A (ko) | 2023-02-21 |
| EP4164634A4 (en) | 2024-08-14 |
| WO2021257353A1 (en) | 2021-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023005855A (es) | Inhibidores de calicreina plasmatica. | |
| MX2022016321A (es) | Inhibidores de la calicreina plasmatica. | |
| MX2021008342A (es) | Derivados de pirazol como inhibidores de calicreina plasmatica. | |
| MX2024001893A (es) | Compuestos heterociclicos y metodos de uso. | |
| MX2023012726A (es) | Compuestos heterociclicos y metodos de uso. | |
| JOP20240216A1 (ar) | مثبطات kras g12c | |
| PH12021550931A1 (en) | New anthelmintic compounds | |
| PH12020500257A1 (en) | Quinoline derivatives for treating infections with helminths | |
| WO2020104648A3 (en) | TGFβ INHIBITOR AND PRODRUGS | |
| CR20190595A (es) | Nuevos derivados de azaquinolina | |
| NO20070258L (no) | Benzyltriazolonforbindelser som ikke-nukleoside revers transkriptase inhibitorer | |
| EP1258252A4 (en) | INHIBITORS OF INTEGRINEXPRESSION | |
| PH12021552555A1 (en) | Dihydroorotate dehydrogenase inhibitors | |
| PH12022550045A1 (en) | Plasma kallikrein inhibitors | |
| PH12022550491A1 (en) | Perk inhibiting pyrrolopyrimidine compounds | |
| MX2022009197A (es) | Metodos de tratamiento para deficiencia de alfa-1 antitripsina. | |
| PH12022550497A1 (en) | Perk inhibiting compounds | |
| MX2022008487A (es) | Degradadores de smarca2-vhl. | |
| JOP20220227A1 (ar) | مركبات بيرولو بيريميدين أمينات كمثبطات للمُتَمِّمِة | |
| MA43052B1 (fr) | Inhibiteurs de la kallicréine plasmatique humaine | |
| MX2023001296A (es) | Composiciones y metodos para tratar enfermedades y trastornos. | |
| MX2023005913A (es) | Derivados de bencenosulfonamida y usos de los mismos. | |
| MX2023000507A (es) | Inhibidores de la calicreina plasmatica. | |
| MX2024009122A (es) | Inhibidores de calicreina plasmatica. | |
| MX2025015694A (es) | Compuestos de formamida heteroaromáticos y usos de los mismos en medicina |